Zhou, Yitian
Lauschke, Volker M. http://orcid.org/0000-0002-1140-6204
Funding for this research was provided by:
Vetenskapsrådet (2016-01153, 2016-01154, 2019-01837)
Innovative Medicines Initiative (875510)
Horizon 2020 Framework Programme (668353)
Karolinska Institute
Article History
Received: 10 August 2021
Accepted: 5 October 2021
First Online: 15 October 2021
Declarations
:
: YZ and VML are co-founders and shareholders of PersoMedix AB. In addition, VML is CEO and shareholder of HepaPredict AB and discloses consultancy work for Enginzyme AB.